• Skip to main content

DistilINFO LifeSciences

Weekly round up from Life Sciences Industry.

  • Publications
    • Home
    • DistilINFO HealthPlan
    • DistilINFO HospitalIT
    • DistilINFO IT
    • DistilINFO Retail
    • DistilINFO POPHealth
    • DistilINFO Ageing
    • DistilINFO Life Sciences
    • DistilINFO GovHealth
    • DistilINFO EHS
    • DistilINFO HealthIndia
    • Subscribe
    • Submit Article
    • Advertise
    • Newsletters

5 Groundbreaking Findings from the Stanford and Apple Heart Study

Share:

April 2, 2019

Stanford Medicine researchers recently released preliminary results of the Apple Heart Study, the largest study ever of its kind, which enrolled over 400,000 participants from all 50 states in a span of only eight months.

Apple Heart Study Overview

Presented at American College of Cardiology’s 68th Annual Scientific Session and Expo in New Orleans, the study was launched in 2017 to evaluate Apple Watch’s irregular rhythm notification, which occasionally checks the heart’s rhythm in the background and sends a notification if an irregular heart rhythm appears to be suggestive of atrial fibrillation. AFib can lead to that can lead to blood clots, stroke, heart failure, and other heart-related complications.

As part of the study, if an irregular heart rhythm was identified, participants received a notification on their Apple Watch and iPhone, a telehealth consultation with a doctor through AmericanWell and an electrocardiogram patch through BioTelemetry for additional monitoring.

Want to publish your own articles on DistilINFO Publications?

Send us an email, we will get in touch with you.

Apple Heart Study Key Findings/Results

Here are five key findings from the massive Apple Heart study:

1. 0.5 percent of the over 400,000 participants received an irregular heart rhythm notification, illustrating the feature’s ability to give a user important health information without creating an unnecessary burden to their doctor’s schedule.

2. Comparisons between irregular pulse-detection on Apple Watch and simultaneous electrocardiography patch recordings showed the pulse detection algorithm (indicating a positive tachogram reading) has a 71 percent positive predictive value.

3. Eighty-four percent of the time, participants who received irregular pulse notifications were found to be in atrial fibrillation at the time of the notification.

4. One-third (34 percent) of the participants who received irregular pulse notifications and followed up by using an ECG patch over a week later were found to have atrial fibrillation. Since atrial fibrillation is an intermittent condition, it’s not surprising for it to go undetected in subsequent ECG patch monitoring.

5. 57 percent of the participants sought medical advice following their irregular rhythm notification, using the information to have more meaningful conversations with their doctors.

Impact of Apple Heart Study for Connected Health

“The results of the Apple Heart Study highlight the potential role that innovative digital technology can play in creating more predictive and preventive health care,” said Lloyd Minor, MD, dean of the Stanford School of Medicine. “Atrial fibrillation is just the beginning, as this study opens the door to further research into wearable technologies and how they might be used to prevent disease before it strikes — a key goal of precision health.”

“The study’s findings have the potential to help patients and clinicians understand how devices like the Apple Watch can play a role in detecting conditions such as atrial fibrillation, a deadly and often undiagnosed disease,” said Mintu Turakhia, MD, associate professor of cardiovascular medicine and principal investigator for the study. “The virtual design of this study also provides a strong foundation upon which future research can be conducted to explore the health implications of wearable technology.”

Date: April 02, 2019

Source: HIT Consultant

Coffee with DistilINFO's Morning Updates...

Sign up for DistilINFO e-Newsletters.

Just a little bit more about you...
PROCEED
Choose Lists
BACK

Related Stories

  • GlobalFit Acquires The Charge Group In Cash And Stock DealGlobalFit Acquires The Charge Group In Cash And Stock Deal
  • Veracyte Completes Acquisition of C2i GenomicsVeracyte Completes Acquisition of C2i Genomics
  • Duke, Deerfield Management Form Four Points Innovation to Invest up $130M in Drug DiscoveryDuke, Deerfield Management Form Four Points Innovation to Invest up $130M in Drug Discovery
  • Variantyx Nabs $41.1M for Tech-Backed Genomic AnalysisVariantyx Nabs $41.1M for Tech-Backed Genomic Analysis
  • Labcorp Partners for At-Home Sample CollectionLabcorp Partners for At-Home Sample Collection
  • Patientpoint Merges with Outcome Health to Form Combined Patient Engagement EntityPatientpoint Merges with Outcome Health to Form Combined Patient Engagement Entity
  • Greenwich LifeSciences Builds Internal Clinical Trial TeamGreenwich LifeSciences Builds Internal Clinical Trial Team
  • J&J Snaps Up Momenta Pharmaceuticals in $6.5 Billion All-Cash DealJ&J Snaps Up Momenta Pharmaceuticals in $6.5 Billion All-Cash Deal

Trending This Week

Sorry. No data so far.

About Us

DistilINFO is media company that publishes Industry news, views and Interviews. We distil the information for you – saving time and keeping you up to date on your interest areas.

More About Us

Follow Us


Useful Links

  • Subscribe
  • Contact
  • Advertise
  • Privacy Policy
  • Terms of Service
  • Feedback

All Publications

  • DistilINFO HealthPlan Advisory
  • DistilINFO HospitalIT Advisory
  • DistilINFO IT Advisory
  • DistilINFO Retail Advisory
  • DistilINFO POPHealth Advisory
  • DistilINFO Ageing Advisory
  • DistilINFO Life Sciences Advisory
  • DistilINFO GovHealth Advisory
  • DistilINFO EHS Advisory
  • DistilINFO HealthIndia Advisory

© DistilINFO Publications